Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aleve rebound

This article was originally published in The Tan Sheet

Executive Summary

First-quarter sales of Bayer's Aleve (naproxen sodium) jumped 90% to $65.9 mil. compared with the prior-year quarter, recovering from concerns related to COX-2 drugs and a possible NSAID class effect, the firm reported during an April 27 earnings call. Aleve became the firm's second best-selling consumer care product after aspirin, which posted quarterly sales of $195.1 bil., Bayer said. Consumer Care segment sales grew 22.8% to $798 mil. due to "rapid expansion" in Europe and North America, with the acquisition of Roche's OTC unit as a contributing factor. Overall, Bayer grew 12% to $9.32 bil., "mainly attributable" to Healthcare gains...

Topics

UsernamePublicRestriction

Register

PS099318

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel